Liquidia Corporation LQDA is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company currently markets Yutrepia (treprostinil) inhalation powder, approved by the FDA in May 2025 and launched the following month commercially.
LQDA also generates revenues through a profit-sharing agreement with Sandoz for the promotion of its generic treprostinil injection in the United States.
Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia's proprietary PRINT particle engineering technology. The platform is designed to enhance deep lung drug delivery, simplify administration through a low-effort dry-powder inhaler and enable higher dose levels than currently marketed inhaled treprostinil therapies.
Tolerability, the ability to reach an effective dose, and efficacy are driving strong adoption of the drug. The ASCENT study in PH-ILD patients showed that as patients were able to take higher doses of Yutrepia, their walking ability improved progressively, without any increase in cough.
The company supports commercialization through a specialized sales force focused on physicians treating PAH and PH-ILD, as well as stakeholders involved in reimbursement and drug distribution.
Since its launch in June 2025, Yutrepia has emerged as a strong growth driver, generating approximately $300.3 million in sales during the first half of 2026. The therapy has demonstrated robust adoption, 5,900 unique prescriptions since launch and initiated more than 5,000 patients on Yutrepia therapy, with nearly 1,100 physicians prescribing the drug.
LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and Raynaud’s phenomenon associated with systemic sclerosis.
Liquidia is leveraging its expertise in respiratory and vascular diseases to advance a pipeline of novel therapies that could support long-term growth. A key pipeline asset is L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.
LQDA Faces Competition in PAH Market
Yutrepia competes in the PAH market against several approved inhaled prostacyclin therapies, while additional pipeline candidates could intensify competition in the coming years.
Its primary competitor is United Therapeutics' UTHR Tyvaso (treprostinil), the long-established inhaled therapy approved for PAH in 2009 and PH-ILD in 2021.
United Therapeutics also markets Tyvaso DPI, a dry-powder version of treprostinil approved in 2022 for both indications. Demand for this product has been strong.
United Therapeutics is further expanding its PAH franchise. The company highlighted two major regulatory filings — ralinepag tablets for PAH and nebulized Tyvaso for IPF — as potentially significant catalysts for long-term growth. Additional planned filings for ralinepag DPI and treprostinil SMI could further expand UTHR’s pipeline and growth opportunities.
The acquisition of Actelion strengthened pharmaceutical giant Johnson & Johnson’s JNJ position in the PAH market.
Yutrepia also competes with Ventavis (iloprost), marketed by JNJ’s Actelion unit, which has been approved for PAH since 2004.
JNJ’s Uptravi (selexipag) is also approved to treat PAH. Johnson & Johnson has another PAH drug, Opsumit, in its portfolio.
Although Yutrepia's proprietary PRINT technology, strong launch trajectory and increasing physician adoption position it well to gain additional market share, its ability to sustain long-term growth will depend on continued execution, successful differentiation from established therapies and expansion of its presence in an increasingly competitive PAH treatment landscape.
LQDA’s Share Price Performance, Valuation & Estimates
Shares of LQDA have surged 99% year to date compared with the industry’s growth of 11.3%.
Image Source: Zacks Investment Research
Going by the price/sales ratio, LQDA shares currently trade at 6.30X forward sales, higher than the industry’s average of 1.94X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has moved south to $2.57 from $2.97, and that for 2027 EPS has declined to $4.38 from $4.81 in the past 60 days.
Image Source: Zacks Investment Research
LQDA currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Liquidia Corporation (LQDA): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
United Therapeutics Corporation (UTHR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).